0000950170-24-081878.txt : 20240705
0000950170-24-081878.hdr.sgml : 20240705
20240705163002
ACCESSION NUMBER: 0000950170-24-081878
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240703
FILED AS OF DATE: 20240705
DATE AS OF CHANGE: 20240705
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pizzuti Dana
CENTRAL INDEX KEY: 0001948238
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38583
FILM NUMBER: 241102864
MAIL ADDRESS:
STREET 1: C/O CRINETICS PHARMACEUTICALS, INC.
STREET 2: 10222 BARNES CANYON ROAD, BUILDING 2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658247
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 263744114
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-450-6464
MAIL ADDRESS:
STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
ownership.xml
4
X0508
4
2024-07-03
false
0001658247
Crinetics Pharmaceuticals, Inc.
CRNX
0001948238
Pizzuti Dana
C/O CRINETICS PHARMACEUTICALS, INC.
6055 LUSK BOULEVARD
SAN DIEGO
CA
92121
false
true
false
false
Chief Med and Dev Officer
true
Common Stock
2024-07-03
4
M
false
14375
16.89
A
42882
D
Common Stock
2024-07-03
4
S
false
14375
44.87
D
28507
D
Stock option (Right to Buy)
16.89
2024-07-03
4
M
false
14375
0
D
2032-10-10
Common Stock
14375
153417
D
The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.87 per share. The range of sales prices on the transaction date was $44.24 to $45.55 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Includes 721 shares acquired under the Issuer's Employee Stock Purchase Plan.
The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Marc Wilson, as attorney-in-fact
2024-07-05